Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors.
J Virol
; 87(23): 13035-41, 2013 Dec.
Article
em En
| MEDLINE
| ID: mdl-24027330
ABSTRACT
Proteasome inhibitors (e.g., bortezomib, MG132) are known to enhance adeno-associated virus (AAV) transduction; however, whether this results from pleotropic proteasome inhibition or off-target serine and/or cysteine protease inhibition remains unresolved. Here, we examined recombinant AAV (rAAV) effects of a new proteasome inhibitor, carfilzomib, which specifically inhibits chymotrypsin-like proteasome activity and no other proteases. We determined that proteasome inhibitors act on rAAV through proteasome inhibition and not serine or cysteine protease inhibition, likely through positive changes late in transduction.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Oligopeptídeos
/
Transdução Genética
/
Dependovirus
/
Infecções por Parvoviridae
/
Inibidores de Proteassoma
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article